Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: Postprandial distress syndrome

Ege Altan, Tatsuhiro Masaoka, Ricard Farré, Jan Tack

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.

Original languageEnglish
Pages (from-to)533-544
Number of pages12
JournalExpert Review of Gastroenterology and Hepatology
Volume6
Issue number5
DOIs
Publication statusPublished - 2012 Sep
Externally publishedYes

Fingerprint

Dyspepsia
Satiation
Japan
Therapeutics
Pain
Gastric Emptying
Muscarinic Receptors
Acetylcholine
Meals
Stomach
Consensus
Placebos
Z 338
Pharmacology
Delivery of Health Care
Neurons
Pharmaceutical Preparations

Keywords

  • acotiamide
  • early satiation
  • functional dyspepsia
  • gastric accommodation
  • gastric emptying
  • postprandial fullness
  • randomized-controlled trial

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia : Postprandial distress syndrome. / Altan, Ege; Masaoka, Tatsuhiro; Farré, Ricard; Tack, Jan.

In: Expert Review of Gastroenterology and Hepatology, Vol. 6, No. 5, 09.2012, p. 533-544.

Research output: Contribution to journalArticle

@article{42aae8023ad94f899551244d4d222d9d,
title = "Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: Postprandial distress syndrome",
abstract = "Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.",
keywords = "acotiamide, early satiation, functional dyspepsia, gastric accommodation, gastric emptying, postprandial fullness, randomized-controlled trial",
author = "Ege Altan and Tatsuhiro Masaoka and Ricard Farr{\'e} and Jan Tack",
year = "2012",
month = "9",
doi = "10.1586/egh.12.34",
language = "English",
volume = "6",
pages = "533--544",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia

T2 - Postprandial distress syndrome

AU - Altan, Ege

AU - Masaoka, Tatsuhiro

AU - Farré, Ricard

AU - Tack, Jan

PY - 2012/9

Y1 - 2012/9

N2 - Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.

AB - Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.

KW - acotiamide

KW - early satiation

KW - functional dyspepsia

KW - gastric accommodation

KW - gastric emptying

KW - postprandial fullness

KW - randomized-controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84867551602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867551602&partnerID=8YFLogxK

U2 - 10.1586/egh.12.34

DO - 10.1586/egh.12.34

M3 - Article

C2 - 23061703

AN - SCOPUS:84867551602

VL - 6

SP - 533

EP - 544

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 5

ER -